['diabetes mellitus, type 2', 'diabetic nephropathy']
['canagliflozin', 'placebo']

        Inclusion Criteria:

          -  Type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) greater than or equal to (>=)
             6.5 percent (%) and less than or equal to (<=) 12.0%, with an estimated glomerular
             filtration rate (eGFR) of >= 30 milliliter (mL)/minute (min)/1.73meter (m)^2 and less
             than (<) 90 mL/min/1.73 m^2

          -  Participants need to be on a stable maximum tolerated labeled daily dose of an
             angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
             for at least 4 weeks prior to randomization

          -  Must have a urine albumin to creatinine ratio (UACR) of greater than (>) 300 milligram
             (mg)/gram (g) and <= 5000 mg/g

        Exclusion Criteria:

          -  History of diabetic ketoacidosis or type 1 diabetes mellitus

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Renal disease that required treatment with immunosuppressive therapy

          -  Known significant liver disease

          -  Current or history of New York Heart Association (NYHA) Class IV heart failure

          -  Blood potassium level >5.5 millimole (mmol)/liter (L) during Screening
      